scholarly journals New Horizons in the Treatment of Corneal Endothelial Dysfunction

2021 ◽  
Vol 2021 ◽  
pp. 1-11
Author(s):  
Carlos Rocha-de-Lossada ◽  
Rahul Rachwani-Anil ◽  
Davide Borroni ◽  
José-María Sánchez-González ◽  
Raquel Esteves-Marques ◽  
...  
Keyword(s):  
Endothelial Dysfunction ◽  
Randomized Clinical Trials ◽  
Kinase Inhibitors ◽  
Rho Kinase ◽  
Corneal Transplant ◽  
Endothelial Keratoplasty ◽  
Revolutionary Change ◽  
Rho Kinase Inhibitors ◽  
Corneal Endothelial Dysfunction ◽  
New Treatments

The treatment of corneal endothelial dysfunction has experienced a revolutionary change in the past decades with the emergence of endothelial keratoplasty techniques: descemet stripping automated endothelial keratoplasty (DSAEK) and descemet membrane endothelial keratoplasty (DMEK). Recently, new treatments such as cultivated endothelial cell therapy, Rho-kinase inhibitors (ROCK inhibitors), bioengineered grafts, and gene therapy have been described. These techniques represent new lines of treatment for endothelial dysfunction. Their advantages are to help address the shortage of quality endothelial tissue, decrease the complications associated with tissue rejection, and reduce the burden of postoperative care following transplantation. Although further randomized clinical trials are required to validate these findings and prove the long-term efficacy of the treatments, the positive outcomes in preliminary clinical studies are a stepping stone to a promising future. Our aim is to review the latest available alternatives and advancements to endothelial corneal transplant.

scholarly journals Evolving Therapies for Fuchs Endothelial Dystrophy

2018 ◽  
Vol 12 (1) ◽  
pp. 26
Author(s):  
Jodhbir Singh Mehta ◽  
Yu Qiang Soh ◽  
Viridiana Kocaba ◽  
◽  
◽  
...  
Keyword(s):  
Kinase Inhibitors ◽  
Corneal Transplantation ◽  
Rho Kinase ◽  
Corneal Dystrophy ◽  
Significant Shift ◽  
Endothelial Keratoplasty ◽  
Early Clinical Trial ◽  
Descemet Membrane ◽  
Rho Kinase Inhibitors ◽  
Fuchs Endothelial Dystrophy

Fuchs endothelial corneal dystrophy (FED) is one of the leading indications for corneal transplantation. Over the last two decades we have seen a significant shift in transplantation procedures for endothelial disease away from penetrating keratoplasty to small incision procedures such as Descemet stripping automated endothelial keratoplasty and Descemet membrane endothelial keratoplasty. More recently, even newer concepts have come to light to explore options of regenerative therapy for FED, e.g. Descemet stripping without endothelial keratoplasty, Descemet membrane transplantation and the use of adjuncts such as Rho kinase inhibitors. Furthermore, alternative strategies involving tissue engineering approaches with the use of cell therapy are also reaching early clinical trial stage. With more information on the underlying genetic abnormalities in FED, gene therapy may be a possible future treatment.

Probing Cellular Outcomes Using Heterobivalent Constructs

2019 ◽  
Author(s):  
Rohit Bhadoria ◽  
Kefeng Ping ◽  
Christer Lohk ◽  
Ivar Järving ◽  
Pavel Starkov
Keyword(s):  
Cell Viability ◽  
Small Molecules ◽  
Cellular Uptake ◽  
Kinase Inhibitors ◽  
Rho Kinase ◽  
Intracellular Delivery ◽  
Rho Kinase Inhibitors

<div> <div> <div> <p>Conjugation techniques are central to improving intracellular delivery of bioactive small molecules. However, tracking and assessing the overall biological outcome of these constructs remains poorly understood. We addressed this issue by having developed a focused library of heterobivalent constructs based on Rho kinase inhibitors to probe various scenarios. By comparing induction of a phenotype of interest vs. cell viability vs. cellular uptake, we demonstrate that such conjugates indeed lead to divergent cellular outcomes. </p> </div> </div> </div>

scholarly journals Neovascular Macular Degeneration: A Review of Etiology, Risk Factors, and Recent Advances in Research and Therapy

2021 ◽  
Vol 22 (3) ◽  
pp. 1170
Author(s):  
Arunbalaji Pugazhendhi ◽  
Margaret Hubbell ◽  
Pooja Jairam ◽  
Balamurali Ambati
Keyword(s):  
Risk Factors ◽  
Macular Degeneration ◽  
Kinase Inhibitors ◽  
Rho Kinase ◽  
The Elderly ◽  
Age Related Macular Degeneration ◽  
Gene Therapies ◽  
Rho Kinase Inhibitors ◽  
Age Related ◽  
Endothelial Growth Factor

Neovascular age-related macular degeneration (exudative or wet AMD) is a prevalent, progressive retinal degenerative macular disease that is characterized by neovascularization of the choroid, mainly affecting the elderly population causing gradual vision impairment. Risk factors such as age, race, genetics, iris color, smoking, drinking, BMI, and diet all play a part in nvAMD’s progression, with anti-vascular endothelial growth factor (anti-VEGF) therapy being the mainstay of treatment. Current therapeutic advancements slow the progression of the disease but do not cure or reverse its course. Newer therapies such as gene therapies, Rho-kinase inhibitors, and levodopa offer potential new targets for treatment.

scholarly journals Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics

2015 ◽  
Vol 131 ◽  
pp. 105-119 ◽  
Author(s):  
Sarah Van de Velde ◽  
Lies De Groef ◽  
Ingeborg Stalmans ◽  
Lieve Moons ◽  
Inge Van Hove
Keyword(s):  
Axonal Regeneration ◽  
Kinase Inhibitors ◽  
Rho Kinase ◽  
Rho Kinase Inhibitors

scholarly journals Fragment-Based and Structure-Guided Discovery and Optimization of Rho Kinase Inhibitors

2012 ◽  
Vol 55 (5) ◽  
pp. 2474-2478 ◽  
Author(s):  
Rongshi Li ◽  
Mathew P. Martin ◽  
Yan Liu ◽  
Binglin Wang ◽  
Ronil A. Patel ◽  
...  
Keyword(s):  
Kinase Inhibitors ◽  
Rho Kinase ◽  
Guided Discovery ◽  
Rho Kinase Inhibitors
Sign in / Sign up

Export Citation Format

Share Document